Abstract In our study, three series of hydroxamate, 2-aminobenzamide, and trifluoromethyl ketone analogues have been designed and synthesized. The synthesized compounds were investigated for their in vitro antiproliferative activities using the MTT-based assay against three human cancer cell lines including A549, NCI-H661, and U937. Most analogues exhibited higher antiproliferative activities against human acute myeloid leukemia cell U937 than the other two human lung cancer cell lines. Furthermore, the compounds were examined against HDAC1, 2, and 8 isoforms. Docking study of compounds 6h, 9b, and 10a suggested that they might bind tightly to the binding pocket of HDAC2 and/or HDAC8. The results suggest that these compounds might have potential as lead compounds for the development of anti-tumor drugs with HDACs inhibitory activities.
|Original language||English (US)|
|Number of pages||15|
|Journal||Bioorganic and Medicinal Chemistry|
|State||Published - 2015|
Bibliographical noteFunding Information:
This work is supported by The Fundamental Research Funds for the Central Universities ( 2242014R30019 ), Technology Supporting Program of Jiangsu Province ( BE2012657 ), and National Basin Research Program of China (No. 2011CB933503 ). We thank the Minnesota Supercomputing Institute for their support for our molecular modeling study.
© 2015 Elsevier Ltd.
- Antiproliferative activity
- Docking simulation
- Histone deacetylases (HDAC)
- Trifluoromethyl ketone